Table 3 Patient characteristics.

From: Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

Age (years)

N = 55 (100%)

 Median

51

 Range

27–72

Race

 Asian

55 (100%)

Sex

 Male

17 (30.9%)

 Female

38 (69.1%)

Tumor site

 Acral

24 (43.6%)

 Mucosal

8 (14.5%)

 Cutaneous

18 (32.7%)

 Unknown

5 (9.1%)

Tumor thickness

 ≤1 mm

0

 >1–2 mm

4 (7.3%)

 >2–4 mm

4 (7.3%)

 >4 mm

18 (32.7%)

 Unknown

29 (52.7%)

Ulceration

 With

22 (40.0%)

 Without

8 (14.5%)

 Unknown

25 (45.5%)

Metastasis status

 IIIC

10 (18.2%)

 M1a

16 (29.1%)

 M1b

18 (32.7%)

 M1c

11 (20.0%)

Efficacy

 CR

1 (1.8%)

 PR

13 (23.6%)

 SD

6 (10.9%)

 PD

35 (63.6%)

Back to article page